PMA device
4Kscore Test
Opko Health, Inc. · Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF, Class III) · First FDA decision Dec 7, 2021, newest Jul 25, 2025Prostate cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "4Kscore"
MAUDE reports
371
Brand "4Kscore", since 2015
PubMed studies
124
Mentioning "4Kscore"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing 4Kscore Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- 4Kscore TestPMA supplement
P190022-S003 · Decided Jul 25, 2025 · 178 days after receipt · Normal 180 Day Track
Device type: Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF) · Laboratory Medicine & Pathology
- 4Kscore TestPMA supplement
P190022-S001 · Decided Jan 8, 2024 · 137 days after receipt · Normal 180 Day Track No User Fee
Device type: Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF) · Laboratory Medicine & Pathology
- 4Kscore TestPMA
P190022 · Decided Dec 7, 2021 · 823 days after receipt
Device type: Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- 4Kscore Test AlgorithmLocal determinationIn effectL37798First Coast Service Options, Inc.Updated Nov 15, 2019
- 4Kscore Test AlgorithmLocal determinationIn effectL37792Novitas Solutions, Inc.Updated Nov 8, 2019
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Codes That Are Not Covered by Medicare (Removal of ICD-9-CM Code V76.44, Prostate Cancer Screening, From the List)Coding analysisReview closedCAG-00297NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "4Kscore", any status and sponsor, newest update first.
No registered device study names "4Kscore".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "4Kscore", and for the whole product code for context.
This brand
371 reports: 371 malfunction, 0 injury, 0 death
Whole product code QRF
371 reports: 371 malfunction, 0 injury, 0 death
Newest reports for this brand
- 4KSCORE TESTMalfunction
3003652672-2022-00370 · Received May 26, 2023 · Event dated Oct 14, 2022
Device type: Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)
Device problem as coded: Application Program Version or Upgrade Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- 4KSCORE TESTMalfunction
3003652672-2022-00368 · Received May 26, 2023 · Event dated Nov 2, 2022
Device type: Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)
Device problem as coded: Application Program Version or Upgrade Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- 4KSCORE TESTMalfunction
3003652672-2022-00367 · Received May 26, 2023 · Event dated Nov 1, 2022
Device type: Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)
Device problem as coded: Application Program Version or Upgrade Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0516-2024 · Started Oct 31, 2023 · Posted by FDA Dec 8, 2023
Reason given: Mathematical modeling of the 4Kscore with and without DRE information was recently performed on over 3,000 specimens. DRE information is a required component of The 4Kscore Test.
Cause as FDA categorized it: Device Design · Device type: Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)
Z-1676-2023 · Started Nov 18, 2022 · Posted by FDA Jun 2, 2023
Reason given: SPM software anomalies that may lead to the generation of erroneous 4Kscore Test results
Cause as FDA categorized it: Software Design Change · Device type: Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)
Published research
The most relevant PubMed records for "4Kscore"[tiab]. The summary above synthesizes these.
- 4Kscore: Blurring the Lines Between Subjective and Objective Assessment.
Plawker MW · Urol Pract · 2023Editorial
- Optimum threshold of the 4Kscore for biopsy in men with negative or indeterminate multiparametric magnetic resonance imaging.
de Almeida S R, Thomas J, Mason MM, et al. · BJUI Compass · 2023
- Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.
Borque-Fernando Á, Rubio-Briones J, Esteban LM, et al. · Prostate Cancer Prostatic Dis · 2019Research Support, Non-U.S. Gov't
- Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
Josefsson A, Månsson M, Kohestani K, et al. · Eur Urol · 2024
- The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
Konety B, Zappala SM, Parekh DJ, et al. · Rev Urol · 2015
- Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer.
Scuderi S, Tin A, Gandaglia G, et al. · Eur Urol Open Sci · 2023
- A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer.
Bhattu AS, Zappala SM, Parekh DJ, et al. · Urology · 2021Validation Study
- Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.
Hougen HY, Reis IM, Han S, et al. · Prostate Cancer Prostatic Dis · 2025Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Men's Health: Prostate Cancer Screening.
Heidelbaugh JJ, Hadj-Moussa M · FP Essent · 2021
- 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis.
Mi C, Bai L, Yang Y, et al. · Urol Oncol · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial.
Punnen S, Nahar B, Prakash NS, et al. · Eur Urol Focus · 2017Multicenter Study, Research Support, Non-U.S. Gov't
- Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
Hougen HY, Sjoberg DD, Thomas J, et al. · J Urol · 2024
Other devices of this type
Also filed under product code QRF.
- IsoPSA AssayCleveland Diagnostics, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.